Memantine Mylan

Memantine Mylan is available as 10-mg and 20-mg tablets and can only be obtained with a prescription.

Treatment should be started and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer’s disease. Treatment should only be started if a caregiver is available who will regularly monitor the use of Memantine Mylan by the patient.

Memantine Mylan should be given once a day at the same time every day. To prevent side effects, the dose of Memantine Mylan is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg. From week four onwards, the recommended maintenance dose is 20 mg once a day. The tolerance and dose should be assessed within three months after starting treatment, and from then on the benefits of continuing treatment with Memantine Mylan should be reassessed on a regular basis. The dose may need to be reduced in patients who have moderate or severe problems with their kidneys.

For more information, see the package leaflet.

The active substance in Memantine Mylan, memantine, is an antidementia medicine. The cause of Alzheimer’s disease is unknown, but memory loss in the disease is believed to be due to a disturbance of message signals in the brain.

Memantine works by blocking special types of receptor called N-methyl-D-aspartate (NMDA) receptors to which the neurotransmitter glutamate normally attaches. Neurotransmitters are chemicals in the nervous system that allow nerve cells to communicate with one another. Changes in the way glutamate transmits signals within the brain have been linked to the memory loss seen in Alzheimer’s disease. In addition, overstimulation of the NMDA receptors may result in cell damage or death. By blocking NMDA receptors, memantine improves the transmission of signals in the brain and reduces the symptoms of Alzheimer’s disease.

Safety information has been included in the summary of product characteristics and the package leaflet for Memantine Mylan, including the appropriate precautions to be followed by healthcare professionals and patients.

The European Commission granted a marketing authorisation valid throughout the European Union for Memantine Mylan on 22 April 2013.

For more information about treatment with Memantine Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Because Memantine Mylan is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Ebixa. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

Because Memantine Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Memantine Mylan has been shown to have comparable quality and to be bioequivalent to Ebixa. Therefore, the CHMP’s view was that, as for Ebixa, the benefit outweighs the identified risk. The Committee recommended that Memantine Mylan be approved for use in the EU.

Memantine Mylan is a medicine used to treat patients with moderate to severe Alzheimer’s disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour. It contains the active substance memantine.

Memantine Mylan is a ‘generic medicine’. This means that Memantine Mylan is similar to a ‘reference medicine’ already authorised in the EU called Ebixa.